Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
1(25%)
Results Posted
150%(3 trials)
Terminated
1(25%)

Phase Distribution

Ph early_phase_1
1
25%
Ph phase_2
1
25%
Ph phase_1
2
50%

Phase Distribution

3

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Early Phase 1First-in-human
1(25.0%)
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
1(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(2)
Terminated(1)

Detailed Status

Completed2
Active, not recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (25.0%)
Phase 12 (50.0%)
Phase 21 (25.0%)

Trials by Status

active_not_recruiting125%
terminated125%
completed250%

Recent Activity

1 active trials
Showing 4 of 4
active_not_recruitingphase_1

Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC

NCT03042468
completedearly_phase_1

Biodistribution/Reproducibility Ga-68 PSMA-HBED-CC

NCT02952469
terminatedphase_1

177Lu-J591 and 177Lu-PSMA-617 Combination for mCRPC

NCT03545165
completedphase_2

PSMA Imaging of Localized Prostate Cancer

NCT03675451

Clinical Trials (4)

Showing 4 of 4 trials
NCT03042468Phase 1

Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC

Active Not Recruiting
NCT02952469Early Phase 1

Biodistribution/Reproducibility Ga-68 PSMA-HBED-CC

Completed
NCT03545165Phase 1

177Lu-J591 and 177Lu-PSMA-617 Combination for mCRPC

Terminated
NCT03675451Phase 2

PSMA Imaging of Localized Prostate Cancer

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4